News

The FDA has granted a fast track designation to Immune Pharmaceuticals, Inc.’s bertilimumab for the treatment of bullous pemphigoid.

New research says it’s medically possible to use HCV-positive patients as liver donors. Now, a new study finds it’s also cost-effective.

Many first responders were exposed to particulate matter that led to their development of World Trade Center Lung Injury, a collection of chronic respiratory conditions, such as asthma and emphysema.

Interestingly, increased distress led to a higher risk of stroke for women, while distressed men had a higher risk of heart attack.

A whitepaper presents practical, expert opinion-based recommendations for preventing and testing for C difficile infection in the NICU.

The FDA has denied accelerated approval for Pompe disease treatment, AT-GAA. However, plans for a pivotal study are still underway, so approval could be forthcoming.

Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.

There’s no cure for Huntington’s disease, but a new study by investigators in Sweden is exploring potential new approaches to treating the neurodegenerative disease.

Flexible, individualized counseling for HIV patients who also use injection drugs also resulted in improved viral suppression.

Mice treated with ACE inhibitors demonstrated preservation of cognitive function, preserved dendritic complexity, a normal spine number, and significantly less microglial activation.

High Impact Chronic Pain encompasses individuals with chronic pain who also have a disability. Data collected in this study will help improve care for patients with HICP and guide future research.

The risk of acute coronary syndrome recurring after hospitalization was not found to be increased in individuals infected with HIV.

Stay up-to-date on the latest rare disease news by checking out our top 5 articles of the week.

Stay up to date on the latest product recalls issued by the FDA this past week.

The company’s application for mepolizumab vied for it to serve as an add-on therapy to inhaled corticosteroid-based maintenance treatment in patients with COPD, as guided by patient blood eosinophil counts.

The sublingual film therapy has been approved under a 16 mg/ 4 mg dosage strength for the maintenance treatment of opioid dependence, adding to therapy options which include both brand name and generic versions.

Daniel Ontaneda, MD, provides insight into the implications of discovering a new subtype of multiple sclerosis: myelocortical MS.

Though previous research showed telemonitoring and pharmacist consultation helped patients manage blood pressure for about one year, researchers have been unsure whether it would provide sustained, long-term benefits in at-risk patients.

Deaths due to drug overdoses and suicides have contributed to decreasing US life expectancy, but other factors indicate that there is a deeper root cause driving these trends.

ProQR Therapeutics has announced positive interim results from its phase 1/2 clinical trial evaluating QR-110 as a potential treatment for Leber’s congenital amaurosis 10 (LCA10).

A new study of 4,000 Canadian women with asthma found patients who had higher body mass indices, smoked frequently, and had lower education faced higher risks of developing chronic obstructive pulmonary disease.

With another randomized, controlled trial involving patients at high risk for flu complications currently underway, investigators found that baloxavir may provide an option for patients with uncomplicated influenza.

The CDC reports that, while tobacco use has decreased, cardiovascular disease risk factors and rates of cardiovascular management are still in need of improvement.

The first part of a recent phase 1/2a trial has met its primary objectives, demonstrating safety & tolerability of SYNB1618 in healthy volunteers & identifying a suitable dose to evaluate in patients with PKU.

The FDA has approved the first and only easy-to-swallow thickened riluzole liquid for the treatment of amyotrophic lateral sclerosis.

Bruce Trapp, PhD, discusses his team’s recent discovery of a new subtype of multiple sclerosis: myelocortical MS.

Tiglutik, a thickened liquid suspension of riluzole, was developed to ease administration for patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing tablets.

Preliminary findings from WTC Health Program are the first to make the connection among workers at "Ground Zero."